🧬 Doug Drysdale - Cybin - Part 3 | Jumping from BD to M&A | Leveraging Debt for Strategic Acquisitions | The Importance of Cultural Fit in Successful Deals | Making an Impact at Norwich, Alvogen, & Pernix Therapeutics

Part 3 of 4. My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.